Episode 97: Sacituzumab Govitecan in Bladder Cancer

FromThe Uromigos

Start listening View podcast show

Episode 97: Sacituzumab Govitecan in Bladder Cancer

FromThe Uromigos

ratings:

Length:

18 minutes

Released:

May 4, 2021

Format:

Podcast episode

Description

Petros Grivas discusses the recent accelerated approval and JCO paper data.

Released:

May 4, 2021

Format:

Podcast episode

Titles in the series (100)

Broadcasting the latest developments in GU cancer

Skip carousel

Episode 4: Treatment Choices in Front Line Advanced Renal Cancer by The Uromigos
27 min listen
Episode 13: COVID-19 and Hydroxychloroquinine Existing Data and Ongoing Trials by The Uromigos
19 min listen
Episode 20: Treating GU Cancer Patients with acute COVID-19 Infection by The Uromigos
13 min listen
Episode 2: The Current role of IO in Front-line Advanced Urothelial Cancer by The Uromigos
30 min listen
Episode 48: ...and then Germany - Jürgen Gschwend discusses cystectomy for urothelial cancer by The Uromigos
21 min listen
Episode 3: Pembrolizumab in Non-Muscle Invasive Bladder Cancer by The Uromigos
33 min listen
Episode 9: COVID-19 and Cancer: An International Perspective by The Uromigos
22 min listen
Episode 40: The Uromigos World Tour moves to France - Bernard Escudier discusses 2nd line therapy in renal cancer and Tivozanib by The Uromigos
20 min listen
Episode 1: Introduction to Uromigos Podcasts by The Uromigos
3 min listen
Episode 15: COVID-19 and Bladder Cancer Surgery by The Uromigos
15 min listen
Episode 33: Adjuvant Atezolizumab in Urothelial Cancer by The Uromigos
20 min listen
Episode 23: Atezolizumab and Enzalutamide versus Enzalutamide Prostate Cancer by The Uromigos
23 min listen
Episode 6: Urothelial Cancer Highlights from ASCO GU 2020 by The Uromigos
20 min listen
Episode 10: COVID-19 and Renal Cancer: A Patient's Perspective by The Uromigos
27 min listen
Episode 38: The Uromigos Virtual World Tour - starting in Vancouver with Atezolizumab in NMIBC by The Uromigos
20 min listen
Episode 37: Regoratinib (FGFR inhibitor) and Atezolizumab in UC with Jonathan Rosenberg by The Uromigos
18 min listen
Episode 7: The First Uromigos Prostate Cancer Podcast by The Uromigos
26 min listen
Episode 31: A Phase 2 Study of Nivolumab with the Addition of Ipilimumab Upon Progression in Renal Cancer by The Uromigos
25 min listen
Episode 12: COVID-19 in Cancer Patients - The Seattle Experience by The Uromigos
26 min listen
Episode 11: COVID-19 and Immune Checkpoint Inhibitors for the Treatment of Cancer by The Uromigos
18 min listen
Episode 5: Renal Highlights from ASCO GU 2020 by The Uromigos
10 min listen
Episode 36: Dr. Tian Zhang discusses three ASCO bladder cancer abstracts with immune therapy/targeted therapy combinations by The Uromigos
21 min listen
Episode 8: COVID-19 and Cancer Patients by The Uromigos
22 min listen
Episode 14: A Discussion about Tocilizumab and COVID-19 with Dr. Nick Mark from Seattle by The Uromigos
15 min listen
Episode 28: Targeting VHL Syndrome Renal Cancer with a HIF Inhibitor - A Game Changer by The Uromigos
14 min listen
Episode 16: Treatments and Trials for COVID-19 by The Uromigos
26 min listen
Episode 18: COVID-19: Addressing Renal Cancer Patients’ Concerns by The Uromigos
25 min listen
Episode 29: PSMA PET at ASCO 2020 with Mike Morris by The Uromigos
24 min listen
Episode 24: A Study of COVID-19 in Lung Cancer Shows High Mortality by The Uromigos
20 min listen
Episode 17: Dr. Toni Choueiri discusses cancer trials and meetings during COVID-19 by The Uromigos
22 min listen

More Episodes from The Uromigos

Skip carousel

Discover this podcast and so much more

Episode 97: Sacituzumab Govitecan in Bladder Cancer

Episode 97: Sacituzumab Govitecan in Bladder Cancer

Description

Titles in the series (100)

More Episodes from The Uromigos